Early HCC: diagnosis and molecular markers

Area of Science:

• Hepatology
• Oncology
• Molecular Biology

Background:

• Hepatocellular carcinoma (HCC) is a prevalent malignancy, often developing in individuals with chronic liver conditions like hepatitis B and C.
• Early detection of small lesions, recognized as precursors to HCC (dysplastic nodules or early HCC), is vital for patient management.
• The molecular underpinnings of early hepatocarcinogenesis remain largely undefined, with no consistent mutations in classical oncogenes or tumor suppressor genes identified.

Purpose of the Study:

• To investigate the molecular mechanisms of early hepatocarcinogenesis.
• To identify potential molecular markers for the early detection and diagnosis of hepatocellular carcinoma.

Main Methods:

• Comprehensive analysis of gene expression patterns in early-stage HCC.
• Evaluation of candidate molecular markers including HSP70, CAP2, glypican 3, and glutamine synthetase.

Main Results:

• Gene expression profiling has begun to elucidate molecular pathways involved in early liver cancer development.
• Specific genes such as HSP70, CAP2, glypican 3, and glutamine synthetase have emerged as potential molecular markers for early HCC.

Conclusions:

• Early HCC represents a critical stage in liver cancer progression, necessitating further research into its molecular basis.
• The identified molecular markers warrant further investigation for their utility in routine pathological and serum-based early detection of HCC.